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CONTEMPORARY REVIEW
Cardiac Graft Assessment in the Era of 
Machine Perfusion: Current and Future 
Biomarkers
Martina Bona, MMed; Rahel K. Wyss, PhD; Maria Arnold, PhD*; Natalia Méndez-Carmona, PhD*; Maria N. Sanz, PhD*; 
Dominik Günsch , MD; Lucio Barile , PhD; Thierry P. Carrel , MD; Sarah L. Longnus , PhD
ABSTRACT: Heart transplantation remains the treatment of reference for patients experiencing end-stage heart failure; unfortu-
nately, graft availability through conventional donation after brain death is insufficient to meet the demand. Use of extended-
criteria donors or donation after circulatory death has emerged to increase organ availability; however, clinical protocols 
require optimization to limit or prevent damage in hearts possessing greater susceptibility to injury than conventional grafts. 
The emergence of cardiac ex situ machine perfusion not only facilitates the use of extended-criteria donor and donation after 
circulatory death hearts through the avoidance of potentially damaging ischemia during graft storage and transport, it also 
opens the door to multiple opportunities for more sensitive monitoring of graft quality. With this review, we aim to bring to-
gether the current knowledge of biomarkers that hold particular promise for cardiac graft evaluation to improve precision and 
reliability in the identification of hearts for transplantation, thereby facilitating the safe increase in graft availability. Information 
about the utility of potential biomarkers was categorized into 5 themes: (1) functional, (2) metabolic, (3) hormone/prohormone, 
(4) cellular damage/death, and (5) inflammatory markers. Several promising biomarkers are identified, and recommendations 
for potential improvements to current clinical protocols are provided.
Key Words: biomarkers ■ donation after circulatory death ■ ex situ heart perfusion ■ extended-criteria heart donors ■ heart 
transplantation
Heart transplantation is the gold standard treat-ment for improving survival and quality of life in patients with end-stage heart disease; however, 
graft availability through conventional donation after 
brain death (DBD) is insufficient to meet the need for 
all patients.1 The number of patients awaiting cardiac 
transplantation has continuously increased in Europe 
and the United States over the past 20 years.1,2
Approaches to improve cardiac graft availability in-
clude the use of extended-criteria donors (ECDs) or 
donation after circulatory death (DCD). Although re-
ports with ECDs and DCD are encouraging, clinical 
protocols have yet to be optimized. Improved methods 
of graft evaluation are of critical importance, not only 
for ensuring the best patient outcomes by correctly 
identifying suitable grafts and permitting the exclusion 
of grafts with excessive cellular dysfunction and dam-
age,3 but also for the identification and development of 
optimized clinical transplant protocols.
The organ shortage has also stimulated the devel-
opment of ex situ organ perfusion systems as an al-
ternative to conventional static, cold storage that can 
help to improve cardiac graft quality and availability, 
especially in situations in which grafts may be par-
ticularly susceptible to ischemic injury, such as those 
from ECDs or DCD, or when long transport times can-
not be avoided. The Organ Care System Heart (OCS) 
by Transmedics has been developed for continuous, 
normothermic graft perfusion, and several systems, 
such as the Steen Heart Preservation System or the 
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HeartPort System, are currently in development/clini-
cal testing for hypothermic graft perfusion.4 During ex 
situ, machine perfusion (MP) with the OCS, the graft 
is maintained in a beating, unloaded state.3 To evalu-
ate graft quality, variables, such as heart rate, rhythm, 
aortic pressure, coronary flow, and lactate profiles, 
are monitored during organ perfusion.3,5 For stan-
dard-criteria donor hearts preserved with the OCS or 
conventional cold-static storage, 30-day recipient and 
graft survival is similar, as is the incidence of cardiac 
allograft vasculopathy,6 demonstrating the short-term 
safety of this approach.7 Furthermore, with organs 
previously not considered suitable for transplantation 
and/or higher-risk recipients, MP is associated with ex-
cellent short-term outcomes.8 In DCD heart transplan-
tations requiring graft transport between centers, the 
OCS has been used, and patient outcomes are similar 
to those with conventional DBD at 1- and 4-year time 
points.3,9,10 Thus, although still in its early stages, nor-
mothermic perfusion storage with the OCS appears 
promising.
To optimize patient outcomes from all donor 
pools, graft evaluation procedures must also evolve. 
Indeed, transplant criteria for conventional, DBD 
grafts are used; however, hearts meeting these cri-
teria are not necessarily protected from rejection 
or cardiac allograft vasculopathy. Furthermore, in-
creased use of ECDs or DCD may increase the risk 
of transplanting unsuitable donor hearts and lead 
to early graft failure. With DBD, in addition to donor 
inclusion/exclusion criteria, cardiac graft selection 
relies heavily on donor monitoring, and involves con-
sideration of parameters such as blood pressure, 
electrocardiographic changes, periods of hypoten-
sion and/or cardiopulmonary resuscitation, drug 
history, history of hypertension, and the need for ino-
tropic support. Up to two-thirds of potential donor 
hearts are rejected before retrieval on the basis of the 
above criteria; however, none of these criteria alone 
precludes successful transplantation.11 Furthermore, 
up to 50% of retrieved grafts are rejected because of 
heart malfunction detected only after detailed inspec-
tion.11 Thus, on one hand, there is a pool of donor 
organs that is rejected because their posttransplan-
tation function cannot be predicted with confidence, 
whereas on the other hand, resources are wasted in 
the procurement of nonsuitable organs.11 It is there-
fore critical to optimize evaluation strategies to more 
effectively select for grafts in which adequate quality 
is achievable.11,12
Although cardiac grafts from different types of do-
nors are subjected to varying conditions before pro-
curement, multiple markers of damage are likely to be 
relevant regardless of donor type. For example, DCD 
grafts are expected to undergo warm ischemia be-
tween circulatory arrest and procurement; however, 
ischemic damage may also occur during cardiople-
gia with DBD grafts, particularly with older donors.12 
Furthermore, in both DCD and DBD donors, a cate-
cholamine surge occurs before graft procurement. 
This “adrenergic storm” can induce peripheral vaso-
constriction and subsequently lead to transient isch-
emia of organs.13
Taken together, improvement of clinical protocols 
to evaluate donor hearts and predict posttransplant 
function may not only provide better clinical out-
comes, but could aid in expanding the donor pool 
and decreasing the number of patients awaiting 
a suitable graft. A greater consideration of cardiac 
biomarkers is of particular interest in light of recently 
available MP technologies that enable monitoring of 
multiple parameters over time during graft storage 
and transport. With this review, we aim to summa-
rize the current knowledge of biomarkers that hold 
particular promise for cardiac graft evaluation to im-
prove our precision and reliability in the identification 
of hearts for transplantation, thereby facilitating a 
safe increase in graft availability via expansion of the 
donor pool.
METHODS
A systematic literature search of the PubMed data-
base was performed with terms: “(heart or cardiac) 
AND (transplant or transplantation) AND biomarker 
AND (graft evaluation or rejection) NOT kidney NOT 
liver NOT lung NOT pancreas NOT (islet or islets) NOT 
bowel NOT pediatric NOT stem cell.” The search was 
limited to English. A total of 1082 (updated July 24, 
2020) articles were retrieved. All abstracts were re-
viewed to exclude irrelevant publications.
All retained articles underwent in-depth review and 
were assigned to categories of biomarkers according 
to the following indicators: (1) function, (2) metabolism, 
(3) hormone/prohormone, (4) cellular damage/death, 
and (5) inflammation. Additional PubMed searches 
Nonstandard Abbreviations and Acronyms
DAMP damage-associated molecular pattern
DBD donation after brain death
DCD donation after circulatory death
ECD extended-criteria donor
HEP high-energy phosphate
H-FABP heart-type fatty acid binding protein
HSP heat shock protein
MP machine perfusion
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were performed in each specific area to ensure that no 
relevant articles were overlooked. Cited references in 
all retained publications were carefully examined, and 
relevant publications were reviewed in detail. 
Given that interventions to evaluate graft quality 
before heart procurement may not be permitted/
possible with all donors, and that both DBD and 
DCD hearts are exposed to catecholamine storms 
that are potentially damaging to cardiac grafts, we 
have focused our attention on biomarkers monitored 
from the time of procurement until transplantation. 
Aspects considered particularly relevant for cardiac 
biomarkers are summarized in the tables. These in-
clude study model and design, details of biomarker 
sampling, outcomes, and predictive value. Predictive 
value was indicated as “yes” when statistically signif-
icant evidence between the measured predictor and 
outcome was provided (eg, statistically significant 
correlation). Predictive value was indicated as “no” 
when evidence (eg, correlation or receiver operating 
characteristic analysis) was provided, but no statisti-
cally significant relationship was observed. In several 
cases, indirect data were considered to either “sup-
port” or “not support” a predictive value, as indicated 
in tables. 
RESULTS AND DISCUSSION
The introduction of MP technologies holds enormous 
potential for optimizing graft evaluation strategies in 
heart transplantation. Given that cardiac MP is still in its 
infancy, a limited number of studies investigating graft 
evaluation during MP were retrieved with our literature 
searches. Nonetheless, evidence supporting the util-
ity of various biomarkers measured between procure-
ment and transplantation has been reported and is 
summarized in Figure 1 and in the following sections, 




Unlike DBD, antemortem functional graft evaluation 
is generally not performed in DCD, but rather during 
MP or normothermic regional perfusion (Figure  2). 
During MP, contractile function is evaluated by visual 
inspection. Criteria for transplantation acceptance for 
contractile function of the loaded DCD heart during 
normothermic regional perfusion are as follows: car-
diac index >2.5  L/min per m2, central venous pres-
sure <12 mm Hg, pulmonary capillary wedge pressure 
Figure 1. Biomarkers with reported potential value when evaluated during graft management.
cTnI indicates cardiac troponin I; cTnT, cardiac troponin T; gp130, glycoprotein 130; HEP, high-energy phosphates; Hs-cTnT, high-
sensitivity cTnT; HTx, heart transplantation; IL-6, interleukin 6; IL-6R, IL-6 receptor; MP, machine perfusion; O2C, cardiac oxygen 
consumption; O2E, cardiac oxygen efficiency; sTNFR, soluble tumor necrosis factor receptor; TNF-α, tumor necrosis factor-α; and 
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<12 mm Hg, and left ventricular ejection fraction >50% 
on transesophageal echocardiography in human DCD 
transplantation.14
Studies in both porcine and rodent DCD models sup-
port the concept that contractile evaluation during 
MP is of aid in graft evaluation (Table  115–19). White 
and colleagues reported that several contractile pa-
rameters predict simultaneously measured myocar-
dial performance (cardiac output×heart weight−1) in 
a porcine model, whereas end-systolic volume and 
end-systolic pressure-volume relationship were not 
helpful.16 In line with this, Ribeiro and colleagues de-
scribed that invasive and noninvasive measures of 
left ventricle contractility strongly correlated with car-
diac function following transplantation.15 Interestingly, 
several parameters measured during ex vivo, un-
loaded perfusions in rat DCD models have been re-
ported to correlate with cardiac functional recovery 
on reloading.17–19
Notably, functional assessments of DCD grafts 
in clinical practice provided better correlations with 
myocardial performance than metabolic variables 
during MP in several studies.9,14,20 Although the su-
premacy of functional parameters highlights the need 
for an MP device capable of assessing the donor 
heart in a physiologic, loaded mode,16 functional 
assessment has not been evaluated in unloaded 
human hearts. It may be that functional evaluations 
performed in unloaded hearts also provide valuable 
information, which would be highly advantageous 
given that this type of preparation is technically much 
less demanding.
Vascular and Endothelial Function
Coronary vascular dysfunction is common in DBD 
heart recipients. Notably, the index of microvas-
cular resistance, assessed early after heart trans-
plantation, predicts death or retransplantation.21 
Endothelial dysfunction is an early marker for intimal 
thickening and graft atherosclerosis,22 and changes 
in coronary endothelial function predict progres-
sion of allograft vasculopathy after transplantation.23 
Correspondingly, endothelial preservation helps to 
delay allograft vasculopathy.24 As endothelial cells 
are more susceptible to ischemia-reperfusion injury 
than cardiac myocytes, endothelial dysfunction may 
be present even before graft procurement, particu-
larly in DCD hearts.25
Preclinical studies indicate that various measures 
of vascular function correlate with heart recovery in ex 
situ preparations (Table  215,17–19,25–28). Coronary flow 
and the ability of the vasculature to adapt coronary 
flow in response to ischemia and reperfusion (hyper-
emic response; coronary flow reserve) are indicators of 
vascular function. In preclinical models, coronary flow 
in loaded preparations or coronary flow and time to 
peak coronary flow in unloaded preparations consis-
tently correlate with functional outcomes. These find-
ings support the concept that assessment of vascular 
Figure 2. Schematic protocols for conditions before and during heart procurement and storage.
A, Hearts obtained with donation after circulatory death (DCD) are subjected to a period of warm, global ischemia, before procurement. 
In the direct procurement and perfusion protocol (DPP), grafts are stored and transported using normothermic machine perfusion 
(MP). In the normothermic, regional perfusion (NRP) protocol, the heart is reperfused in situ. Only after functional evaluation is it 
procured, stored, and transported using normothermic MP or cold, static storage (CSS). B, Hearts obtained with donation after brain 
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and/or endothelial function in both DCD and DBD 
grafts before transplantation may be particularly prom-
ising for graft evaluation.
Although vascular function is currently monitored 
during MP, its predictive value before transplantation 
remains to be determined.29 One advantage of coro-
nary flow is that continuous measurements can easily 
be obtained during MP. However, coronary flow and 
vascular responses are substantially influenced by 
many factors, such as vasodilatory agents (eg, ade-
nosine), cardiac oxygen demand and perfusate oxy-
gen levels, temperature, and pressure. Thus, within 
individual studies, when procurement and reperfusion 
conditions are maintained, coronary flow may correlate 
well with functional recovery; however, when these 
conditions vary, as would be expected in clinical prac-
tice, it may be less reliable. As such, these parameters 
must be interpreted in light of specific perfusion condi-
tions and may be best used in combination with other 
predictive indicators to offset potential disadvantages 




Cardiac oxygen consumption during MP, in both 
loaded and unloaded conditions, correlates with 
subsequent cardiac function in a small number of 
preclinical DCD studies (Table 315–18). Similar to coro-
nary flow, oxygen consumption is easily measurable 
during MP in venous and arterial perfusate samples 
using a standard blood gas analyzer, but is subject 
to perturbations by multiple factors, including cardiac 
function and coronary flow. One option to improve 
the reliability of oxygen consumption is to consider it 
in combination with contractile function (eg, cardiac 
oxygen efficiency), which correlated well with cardiac 
recovery when measured in unloaded preparations 
in a preclinical DCD model.17
Lactate
The use of lactate profiles during MP for graft evaluation 
has yielded varying results, but may be of greater utility 
in DBD compared with DCD grafts (Table 415–20,30–32). 
Lactate extraction and/or perfusate lactate changes 
over time are currently used as metabolic markers 
for graft quality in heart transplantation during MP.7,8 
Inclusion criteria ([1] net lactate extraction, [2] decreas-
ing or stable perfusate lactate levels, and [3] perfusate 
lactate concentration <5 mmol/L at end MP) are based 
on experience with DBD hearts.7 End-MP lactate con-
centration was defined in DBD hearts as a predictor 
of 30-day graft failure, with a sensitivity of 0.625 and a 
specificity of 0.975.31 Although these criteria have been 
implemented to help identify suitable human5 and por-
cine33,34 DCD grafts for transplantation, a lack of sen-
sitivity for lactate in DCD cardiac graft evaluation has 
been reported.14,20 Indeed, at least 5 of 9 DCD hearts 
with end-MP lactate concentrations >5 mmol/L could 
be transplanted without compromising outcomes.9,14,20 
This lack of sensitivity may result from the fact that sev-
eral factors can affect lactate profiles, including donor 
lactate levels, concentrations of other perfusate energy 
substrates, and erythrocyte metabolic rates. Lactate 
may thus be best used in combination with other bi-
omarkers, and specific criteria/thresholds remain to 
be established for DCD graft evaluation. Interestingly, 
it has recently been reported in a preclinical study of 
mixed DCD and DBD donors that glucose profiles may 
be of greater value in predicting posttransplant heart 
function than those of lactate.35
High-Energy Phosphate Metabolites
Higher levels of cardiac high-energy phosphates 
(HEPs), whether measured at the start, during, or 
after the graft storage period, are associated with 
better graft outcomes in both clinical and preclinical 
studies in DBD, as well as in preclinical DCD reports 
(Table 532,36–43). Furthermore, preclinical reports dem-
onstrate that partial or full replacement of conventional, 
cold, static graft storage with continuous perfusion 
provides better preservation of HEPs and enhances 
contractile function or recovery of function in rat,41–43 
dog,39 and pig32,38 models. Although fewer studies 
have been performed with human grafts, continuous 
perfusion also better preserves HEPs.44 These findings 
are in agreement with the concept that better pres-
ervation of metabolic homeostasis, rather than simply 
limiting metabolic activity, is a superior strategy for op-
timal graft preservation.45
HEPs are of particular interest as they can be rap-
idly quantified during MP by phosphorous-31 mag-
netic resonance spectroscopy in graft biopsies, albeit 
this technology may be limited to research centers. 
However, any individual measurement provides only a 
snapshot of tissue HEP content, whereas changes in 
HEP profiles over time, which may prove particularly 
valuable, require multiple measurements that could be 
obtained with biopsies during MP. Further investiga-
tions are necessary to establish sensitive and reliable 
indicators of graft quality with myocardial HEP content.
Uric Acid
The end product of purine catabolism, uric acid, as a 
marker for various outcomes, when measured in recipi-
ents of DBD hearts, has been investigated in only a few 
studies.46–48 Higher posttransplant uric acid levels are 
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allograft vasculopathy,46 and elevated serum uric acid 
concentrations at 1 year after heart transplant are as-
sociated with an increased risk of mortality compared 
with patients with uric acid levels below the upper 
quartile cutoff.47 However, this may be less donor/graft 
related and more recipient related as hyperuricemia in 
recipients before heart transplant is associated with 
more severe rejection after transplant compared with 
patients with lower uric acid levels.48
In patients with ST-segment–elevation myocardial 
infarction, the prognostic value of circulating uric acid 
has been demonstrated, which may be particularly rel-
evant for DCD graft evaluation. In one study, mortal-
ity in patients with myocardial infarction was reported 
as ≈3.7-fold higher in patients with uric acid concen-
trations in the highest quartile compared with those 
with uric acid concentrations of the lowest quartile.49 
However, in patients with ST-segment–elevation myo-
cardial infarction who underwent percutaneous cor-
onary intervention, intensive care unit complications 
were more prevalent in patients with higher versus 
lower fasting uric acid levels, and intensive care unit 
mortality was not statistically different.50
Although the potential of uric acid shows promise, 




Several clinical studies support a role for brain natriu-
retic peptide (BNP) as a circulating biomarker in DBD 
cardiac graft assessment. BNP is released from ven-
tricular cardiomyocytes in response to various “stress” 
stimuli, such as mechanical stretch, neuroendocrine 
activation, and tachycardia. In the context of DBD, 
donor plasma levels of both BNP and its precursor NT-
proBNP (N-terminal pro-B-type natriuretic peptide), 
when measured around the time of brain death, are 
associated with cardiac function at the time of organ 
procurement and posttransplantation51. Furthermore, 
the accuracy of predicting heart function in DBD do-
nors can be improved by combining simultaneous 
measurements with donor cardiac troponins.51 In ad-
dition, as BNP and NT-proBNP are released in acute 
ischemia, these molecules may be of particular utility 
in DCD.52 To our knowledge, the value of BNP or NT-
proBNP as a biomarker of graft quality, when meas-
ured at the time of, or following, heart procurement has 
not been investigated.
Procalcitonin
Procalcitonin is a precursor of the hormone calci-
tonin and clinically used as a circulating marker of 
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patients have reported that donor plasma procalci-
tonin, when measured at the start of donor manage-
ment or on pericardial opening, negatively correlates 
with cardiac graft function both before procurement 
and posttransplantation.53–55 Furthermore, procalci-
tonin, measured immediately before pericardial open-
ing, is an independent predictor of early graft failure 
in DBD.54,55 Although procalcitonin may be elevated 
as a result of brain death, the precise stimulus and 
cell type responsible for its release are unknown.56 
As with BNP/NT-proBNP, the utility of procalcitonin, 
when measured at later stages of heart transplanta-
tion or in DCD heart transplantation, has not been 
investigated.
Copeptin
Copeptin may predict postoperative outcomes in heart 
transplant patients,57 but to our knowledge, it has not 
been investigated in cardiac grafts. Copeptin is a por-
tion of the prevasopressin-provasopressin molecule 
secreted by the hypothalamus and is emerging as a 
biomarker in various cardiac diseases, such as heart 
failure and acute coronary syndrome.58 Copeptin is 
measurable in donor blood; however, it is a marker not 
only of cardiac damage, but also of pulmonary dis-
ease, diabetes mellitus insipidus, hemorrhagic shock, 
and ischemic stroke.59 Thus, copeptin assessment 
could contribute information about cardiac cellular 
damage pre–heart transplantation, but likely requires 
interpretation in combination with more cardiac-spe-
cific biomarkers.
Cellular Damage/Death Markers
Although release of cellular damage/death markers 
can provide valuable information about cardiac in-
jury, variable levels, which do not accurately reflect 
graft quality, may be present in donor blood as a re-
sult of previous defibrillation and in cardioplegia or 
MP perfusate solutions as a result of extended cold 
static storage or perioperative damage. These fac-
tors may explain the inconsistent findings for the util-
ity of cardiac troponin T and cardiac troponin I as 
predictors for posttransplant graft function in clini-
cal DBD studies (Table  617–19,54,60–66). When investi-
gated in this context, creatine kinase–muscle/brain 
isozyme levels at pericardial opening did not ap-
pear useful for human DCD graft evaluation.63 Lack 
of predictive value may result from high interpatient 
variability for normal creatine kinase–muscle/brain 
isozyme values, as well as nonheart sources of circu-
lating donor creatine kinase–muscle/brain isozyme 
(ie, skeletal muscle).63 Lactate dehydrogenase was 
of some value in predicting functional recovery in 
a preclinical DCD model during MP19; however, as 
erythrocytes may also release lactate dehydroge-
nase, its utility with blood/erythrocyte-containing 
perfusates is likely limited. H-FABP (heart-type fatty 
acid binding protein) may also be a useful biomarker 
as it is rapidly released from cardiomyocytes follow-
ing ischemic damage.67,68 No study has addressed 
its potential as an indicator of cardiac damage in 
transplantation; however, it appears promising in 
acute myocardial infarction. Xu and colleagues re-
ported a pooled sensitivity of 0.75 and a specificity 
of 0.81 for H-FABP alone in diagnosis of acute myo-
cardial infarction within 6  hours.67 The combination 
of H-FABP with high-sensitivity troponin T improved 
sensitivity, but reduced specificity.67 H-FABP may be 
a particularly valuable indicator of graft damage as 
it can be detected earlier than troponins, from 0.5 
to 1.5 hours,68,69 versus 3 to 6 hours for cardiac tro-
ponin T in acute myocardial infarction.70 Thus, the 
value of H-FABP in heart transplantation graft evalu-




Although preclinical data support the concept that 
endothelial activation is associated with reduced 
posttransplant outcomes, corroborative clinical stud-
ies are lacking (Table 725,71–76). Stoica and colleagues 
demonstrated that endothelial activation (higher lev-
els of P-selectin and vascular cell adhesion molecule 
1) was increased in biopsies of DBD cardiac grafts 
compared with control tissue, but that changes in 
endothelial activation during transplantation are not 
predictive for organ failure.71 Circulating endothelial 
microparticles, submicroscopic membrane vesicles 
released from the surface of endothelial cells dur-
ing activation, injury, and/or apoptosis, are also of 
potential interest as biomarkers.77 Although not yet 
investigated in the setting of graft evaluation, these 
particles indicate increased endothelial apoptosis 
in posttransplant patients.77 Further investigation is 
required to elucidate the relationships between en-
dothelial cell activation and microparticles, rejection, 
and cardiac allograft vasculopathy.
Inflammatory Cytokines
Inflammatory cytokines may be involved in graft dys-
function.75,76 Reports investigating the utility of tumor 
necrosis factor (TNF)-α, soluble TNF receptors 1 and 
2, and interleukin 6 (IL-6) as indicators of posttrans-
plant graft function are presented in Table 7.
TNF-α protein levels can rapidly increase in car-
diac myocytes after brain death and may have neg-
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NO synthase, disruption of excitation-contraction 
coupling and systolic/diastolic function, inflamma-
tion, cardiac myocyte apoptosis, and even heart 
failure.75 Although only few investigations of TNF-α 
in DBD heart transplantation have been reported, 
they consistently demonstrate elevated levels of 
TNF-α in cardiac tissue and donor serum samples 
for hearts with poor myocardial function, as well as 
for hearts that develop right heart failure early after 
transplantation.75
Interleukin 6 is released by immune cells, mesen-
chymal cells, endothelial cells, and fibroblasts, among 
others, into the circulation in response to various stim-
uli. Interleukin 6 has been investigated only in a few 
heart transplantation studies; nonetheless, levels in 
cardiac biopsies or donor blood negatively correlate 
with graft quality and patient outcomes.73,75
Importantly, as donor serum TNF-α levels correlate 
with tissue content in biopsies,76 it may be that biopsy 
measurements could be avoided. Instead, inflam-
matory cytokine profiles of donor blood and/or MP 
perfusate could be evaluated, providing potential ad-
vantages for these biomarkers.
Damage-Associated Molecular Patterns
Tissue and cells undergoing stress or damage, such 
as ischemia-reperfusion injury, release molecules 
collectively termed damage-associated molecular 
patterns (DAMPs). DAMPs are analogous to patho-
gen-associated molecular patterns, with the activa-
tion of innate immunity, which may ultimately lead 
to graft inflammation and early graft dysfunction.78 
DAMPs include the following cellular and extracellu-
lar components: fibrinogen, nucleic acids (RNA and 
DNA), high-mobility group box 1, S100, HSPs (heat 
shock proteins) (HSP70/72, HSP90, and HSP60), 
tenascin c, and histone. Circulating levels of high-
mobility group box 1, S100, HSP70, and tenascin c 
in patients with signs of acute ischemic coronary dis-
ease are potential biomarkers for early diagnosis of 
myocardial infarction.
Similarly, damaged mitochondria also liberate mi-
tochondrial components of the DAMP class, termed 
mitochondrial DAMPs. Recognized mitochondrial 
DAMPs include the following: mitochondrial DNA, 
cytochrome c, ATP, mitochondrial transcription fac-
tor A, N-formyl peptides, succinate, and cardiolipin.79 
Importantly, increased circulating mitochondrial 
DAMPs in both DBD and DCD donors have been 
reported, and donor plasma mitochondrial DNA lev-
els correlate with early allograft dysfunction in liver 
transplant recipients.80 In an isolated rat heart model 
of DCD, we have recently demonstrated that cyto-
chrome c and succinate are released during early 
reperfusion following warm, global ischemia, and 
levels negatively correlate with subsequently mea-
sured functional recovery.17
As DAMPs are ubiquitously expressed, evalua-
tion of release during MP, rather than donor levels, is 
likely to provide superior specificity for cardiac graft 
evaluation.
New Approaches Toward Graft Evaluation
Omics Approaches
Investigation into patterns of changes in genomics 
(gene expression), transcriptomics (mRNA expression), 
proteomics (protein expression and posttranslational 
modifications), and metabolomics (metabolites) in car-
diac grafts may also provide valuable information about 
graft quality. Indeed, mRNA signatures have been re-
ported to detect injury both at procurement and during 
MP in a preclinical DCD model.66 Furthermore, the de-
velopment of pharmacogenomics approaches could 
potentially be used to individualize and optimize drug 
therapy during MP.81
Exosome Profiling
Exosomes, secreted nanovesicles of 50 to 200 nm 
with specific RNA, lipid, and protein content, are 
released into the circulation or body fluids in pa-
tients with various pathological conditions, indicat-
ing a potential role for exosomes as a diagnostic 
tool. Following heart transplantation, recipient den-
dritic cells acquire donor major histocompatibility 
complex molecules by capturing donor-derived ex-
osomes,82 implicating exosomes in the induction of 
antigen-specific effector immune responses.67 This 
exosome-mediated major histocompatibility com-
plex “cross-dressing” in immune homeostasis83 may 
therefore be exploited as a biomarker to monitor 
acute rejection.84
Before transplantation, exosomes extracted from 
heart perfusate may reflect the pathophysiological sta-
tus of the donor cells and organ. The number of donor 
exosomes has been demonstrated to correlate with 
organ stability/rejection in a mouse heart transplanta-
tion model.69 Importantly, cardiac myosin and vimentin 
are recognized as tissue-restricted self-antigens that 
are detectable on the surface of circulating exosomes 
and are associated with primary graft dysfunction.85 
Even before cell membrane rupture, cardiomyocytes 
can release cardiac myosin and vimentin in associa-
tion with exosomes. Not only are structural proteins 
enveloped in exosomes of damaged, but nondis-
rupted, cardiomyocytes, recently Hu et al showed that 
apoptosis-related proteins are enriched in exosomes 
released by cardiomyocytes subjected to oxidative 
stress.86 Thus, it is plausible that following the cate-
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or graft ischemia-reperfusion injury, damaged cells re-
lease exosomes into the circulation, which could lead 
to sensitization and eventually rejection in the recipient. 
Thus, exosomes may be of particular interest for graft 
evaluation not only posttransplantation to monitor re-
jection, but also in donor blood and/or in graft perfu-
sate during MP.
Cardiac Imaging
Imaging techniques are already used to assess cardiac 
graft function in DBD donors; however, this may not be 
possible in all situations, particularly in DCD.
Echocardiography can assess myocardial func-
tion and anatomical structural abnormalities. With the 
Doppler technique to assess anatomic information, 
pressure gradients, and blood flow velocities, echo-
cardiography can help in the diagnosis and grading of 
cardiac disease. Echocardiography is part of the stan-
dard donor heart evaluation procedure in DBD and is 
also used to assess DCD graft function during normo-
thermic regional perfusion.14 Despite strict limitations 
on antemortem interventions in DCD, Chew et al10 
reported the use of echocardiography to assess the 
function of potential donor hearts before withdrawal of 
life-sustaining therapy.
X-ray fluoroscopy is one of the most common 
examinations for imaging the coronary arteries. The 
utility of coronary angiography in donor heart as-
sessment during MP has been demonstrated in 2 
case reports.87,88 Cardiac computed tomography 
is frequently used as a low-radiation alternative, for 
noninvasive, rapid screening for both coronary artery 
stenosis and structural abnormalities, such as valve 
disease.89
Nuclear imaging techniques have long been es-
tablished, and new tracers are being developed con-
stantly.90 With radioactive tracers, various metabolic 
pathways can be investigated using single-photon 
emission computed tomography or positron emis-
sion tomography.89 Disadvantaged by poor spatial 
resolution, fusion imaging methods, such as positron 
emission tomography with computed tomography 
or magnetic resonance imaging, improve accuracy 
of tracer localization and accumulation, and of tissue 
characteristics themselves.
Cardiovascular magnetic resonance is the gold 
standard for assessment of cardiac function, espe-
cially of the right ventricle, which is harder to assess 
with echocardiography as it does not follow a classic 
geometric model.91 Cardiovascular magnetic reso-
nance can be considered a comprehensive examina-
tion as it can also detect many factors, including, but 
not limited to, structural changes, such as fibrosis 
and scar, iron or fat accumulation, or other patholog-
ical conditions.92 It also allows for the detection and 
(semi-) quantitative assessment of myocardial edema, 
which is of prognostic value in inflammatory diseases 
and ischemia.93 The addition of contrast agents per-
mits the detection of fibrosis and scar, as well as the 
assessment of coronary and microvascular func-
tion. More recent approaches focus on exploiting 
endogenous contrast and vasodilation techniques 
to assess microvascular function and myocardial 
oxygenation.94,95 Furthermore, techniques, such as 
parametric mapping, permit quantification of tissue 
characteristics.96 Mapping may be more sensitive 
to early-stage pathological conditions,97 and reader 
bias is eliminated as evaluations are no longer based 
on visual assessment.
Magnetic resonance spectroscopy has mainly been 
used to assess energetic inorganic phosphates as the 
ATP/creatine phosphate ratio noninvasively in vivo,98 
but there are also various other molecules that can 
be traced, permitting measurement of even the de-
oxygenation of heme molecules.99 It is ideally suited 
to studying cardiac metabolism; however, it is re-
stricted to research and possesses limited sensitivity. 
Hyperpolarized metabolic magnetic resonance allows 
real-time metabolic imaging without the need for ra-
dioactive compounds100; however, it is in its infancy in 
humans.
In combination with imaging technologies, MP 
opens the door to new, ex situ possibilities, with the 
advantages of permitting imaging after the heart has 
already been exposed to potentially damaging condi-
tions, such as warm ischemia and reperfusion in DCD, 
and the ability to monitor multiple variables rapidly. 
Nonetheless, the use of contrast agents must be care-
fully considered, and purpose-built perfusion systems 
may be required.
CONCLUSIONS
Major obstacles in heart transplantation include insuf-
ficient donor organs and high rates of primary graft 
dysfunction. Improved protocols for cardiac graft eval-
uation may not only aid in expanding the donor pool, 
but may also provide better clinical outcomes by help-
ing to identify grafts at risk for primary dysfunction. A 
greater consideration of cardiac biomarkers, be they 
measured at procurement, during static storage, and/
or during MP, holds potential for developing clinical 
protocols that allow a more precise and reliable evalua-
tion of graft suitability for transplantation. This is of par-
ticular interest, on one hand, in light of increasing use 
of ECDs and DCD, which may require more sophisti-
cated graft evaluation techniques; and, on the other 
hand, as cardiac MP options, which enable monitoring 
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In this review, we have identified and summa-
rized particularly promising approaches in the devel-
opment of biomarkers for cardiac graft quality and 
provided indications for the time window of assess-
ment (Figure 3). Importantly, MP allows monitoring of 
changes in biomarker release over time via perfusate 
sampling. This possibility should permit more precise 
graft evaluation. Nonetheless, identification of reliable 
predictive parameters will require standardization of 
perfusion conditions, such as perfusion temperature, 
composition, and pressure, as well as chronotropy 
and inotropy. Furthermore, techniques must permit 
timely biomarker measure evaluation to fit within the 
time frame of clinical heart transplantation protocols. 
Several biomarkers, such as troponins and lactate, 
are rapidly and routinely measured in clinical practice 
and could be implemented without difficulty. However, 
other approaches, such as HEP or exosome profil-
ing, which may be of particular value in graft evalu-
ation, require further development to establish rapid 
measurement protocols and appropriate thresholds/
criteria. Importantly, the combined use of several bio-
marker measurements would likely provide the most 
robust assessment. Current imaging modalities could 
also be used to evaluate cardiac grafts, permitting de-
tailed graft characterization. Of particular relevance 
are techniques that enable the assessment of meta-
bolic flux and allow optimization of the perfusion en-
vironment with a high potential for translatability and 
graft assessment before transplant without the need 
for radioactive tracers. Although MP systems must be 
specially adapted for computed tomography and car-
diovascular magnetic resonance, imaging modalities 
are particularly attractive as several graft characteris-
tics can be simultaneously evaluated. Cardiovascular 
magnetic resonance is of particular promise as it pos-
sesses excellent spatial and temporal resolution, it is 
not limited by poor ultrasound windows, as may occur 
with echocardiography, and does not use ionizing 
radiation.
Figure 3. Schematic overview of markers for cardiac graft evaluation.
Markers can be assessed at the level of the whole organ (blue), tissue biopsies (red), or circulating in donor blood or ex situ perfusate 
(green). Cardiac metabolism: cardiac oxygen consumption and efficiency, lactate release, and high-energy phosphate metabolites. 
Tissue injury: cardiac troponin I and cardiac troponin T. Endothelial activation: P-, E-, and L-selectin expression, vascular cell adhesion 
molecule-1, and thrombomodulin. Vascular function: coronary flow, vascular relaxation, vascular leakage (edema), and endothelial NO 
synthase coupling (peroxynitrite formation). Inflammation: tumor necrosis factor (TNF)-α, interleukin 6, interleukin 10, glycoprotein 
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